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SARS-CoV-2 is the third known coronavirus within the past 18 years 
to cause severe respiratory illness, its predecessors being severe acute 
respiratory syndrome (SARS) in 2002 and Middle East respiratory 
syndrome (MERS) in 2012.[1,2] Although the case fatality rate of 
SARS-CoV-2 infection is lower than those for SARS and MERS, 
COVID-19 has caused far greater loss of human life.[1,3]
SARS-CoV-2 enters the host predominantly via angiotensin-
converting enzyme 2 receptors on pulmonary alveolar type 2 cells, 
causing in its most severe form widespread alveolar damage with 
microvascular thrombosis. If the initial innate antiviral immune 
response is unsuccessful in its attempts to eliminate the pathogen, 
a complex immune response ensues, characterised by excess 
proinflammatory mediators such as interleukin-2, interleukin-6 
(IL-6), interleukin-7, interleukin-10, granulocyte colony-stimu-
lating factor, interferon-gamma-induced protein 10, monocyte 
chemoattractant protein-1, macrophage inflammatory protein-1A, 
tumour necrosis factor, and a dysregulated interferon response. This 
cytokine storm further inhibits adequate T-cell responses, potentially 
progressing to severe disease with ARDS, multiorgan dysfunction 
and death.[1,2,4-7]
Several therapeutic interventions are continuously being investi -
gated, with a multitude of trials underway investigating treatment 
strategies based on the stage of disease progression. As per the South 
African (SA) National Department of Health (NDoH) rapid review 
summaries of 2020, only the correct use of corticosteroid therapy has 
been shown to have mortality benefit in the management of COVID-19.[8]
The use of corticosteroids in the treatment of COVID-19 was 
controversial in the early stages of the pandemic.[2] Based on 
earlier studies of SARS and MERS, the World Health Organization 
(WHO) advised against the routine use of corticosteroids owing 
to lack of mortality benefit, delay in viral clearance and the risk of 
steroid-related side-effects.[1,9] Throughout the early phase of the 
pandemic corticosteroid use was variable, but owing to the IL-6-
driven hyperinflammation and subsequent cytokine storm evident in 
the critically ill, various institutions opted to include corticosteroids 
as part of their standard of care for severe COVID-19.[1,3,4,10]
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Background. The hyperinflammation seen as part of a dysregulated immune response to SARS-CoV-2 in its most severe form leads 
to acute respiratory distress syndrome (ARDS), multiorgan failure and death. Corticosteroid therapy targets this hyperinflammation, 
otherwise known as a cytokine storm. It is the only therapeutic agent to date with a mortality benefit, with clear guidelines from national 
and international health authorities guiding its use.
Objectives. To compare severity-of-illness indices, survival, length of intensive care unit (ICU) stay and potential ICU complications in patients 
treated with different corticosteroid regimens (high-dose hydrocortisone, high-dose methylprednisolone and lower-dose dexamethasone).
Methods. In this single-centre descriptive retrospective observational study of a cohort of patients with severe COVID-19 admitted to a 
COVID-dedicated ICU, we compared patients treated with the three different corticosteroid regimens.
Results. In 242 cases we could not demonstrate any statistically or clinically significant difference in the outcome of patients with critical 
COVID-19 treated with high-dose intravenous hydrocortisone (n=88) or methylprednisolone (n=46) compared with a relatively lower dose 
of dexamethasone (n=108). The survival rates were 38.6%, 39.1% and 33.3%, respectively (p=0.68). Patients treated with methylprednisolone 
tended to have a shorter length of ICU stay (median (interquartile range) 6 (4 - 10), 4 (2 - 8) and 5 (2 - 8) days; p=0.015) and fewer episodes 
of nosocomial sepsis (47.7%, 32.6% and 48.1%; p=0.01).
Conclusions. Hydrocortisone or methylprednisolone can be given as an alternative to dexamethasone in the management of critical 
COVID-19, and this is a feasible alternative, especially in resource-constrained settings.
S Afr Med J 2021;111(6):550-553. https://doi.org/10.7196/SAMJ.2021.v111i6.15582
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The COVID-19 intensive care unit (ICU) at our institution opted 
to include high-dose corticosteroids as of April 2020. High-dose 
intravenous hydrocortisone was used because of its general availability 
and low cost, and was later replaced by high-dose methylprednisolone 
and ultimately lower-dose intravenous dexamethasone after the 
provisional data from the Randomized Evaluation of Covid-19 
Therapy (RECOVERY) trial became available.[11]
Objectives
The main objective of this study was to compare the severity of 
illness indices, survival, length of ICU stay and potential ICU 
complications in patients treated with different corticosteroid 
regimens (hydrocortisone, methylprednisolone and dexamethasone).
Methods
All patients with confirmed SARS-CoV-2 pneumonia admitted 
to the COVID-19 ICU at Tygerberg Hospital, Cape Town, SA, for 
respiratory support were enrolled into a prospective registry. The 
registry was approved by the Health Research Ethics Committee 
(HREC) of Stellenbosch University (ref. no. N20/04/002_COVID-19) 
and Tygerberg Hospital.
We extracted the data on all patients admitted from 26 March to 
18 July 2020 who received at least one dose of a corticosteroid (which 
became standard practice as of 13 April) and excluded patients 
who received none. Data captured included patient demographics, 
comorbidities, laboratory data, indices of severity, length of ICU 
stay, survival, and potential complications related to corticosteroids. 
The indices of disease severity included the sequential organ failure 
assessment (SOFA) score and the arterial oxygen partial pressure to 
fraction of inspired oxygen ratio (PaO2/FiO2). Concomitant use of 
anticoagulants and other pharmacotherapies was documented.
High-flow nasal oxygen (HFNO) therapy was utilised as initial 
oxygenation for patients who were fully awake and co-operative 
at the time of admission, and failure of HFNO (either mechanical 
ventilation or sudden death) was recorded.[12] Therapeutic dose 
anticoagulation with enoxaparin was routinely used unless a clear 
contraindication was present.
We compared the data of three sequential cohorts, patients 
managed with: (i) high-dose intravenous hydrocortisone (100 - 
200  mg 6-hourly); (ii) high-dose intravenous methylprednisolone 
(40 mg 12-hourly); and (iii) lower-dose intravenous dexamethasone 
(8 mg once daily). Intravenous corticosteroids were routinely 
given for 10 - 14 days at the time of the study. The retrospective 
comparison of data was also approved by the HREC of Stellenbosch 
University (ref. no. S20/07/003_COVID-19).
Statistical analysis
Categorical variables were expressed as frequencies and percentages 
and were compared using Pearson’s χ2 tests or Fisher’s exact tests. 
Continuous variables were expressed as medians with interquartile 
ranges (IQRs) and were compared using the Kruskal-Wallis test.
Results
A total of 248 patients were admitted from 26 March to 18 July 2020, 
of whom 242 received intravenous corticosteroids. The baseline 
characteristics and outcome data of the three cohorts are summarised 
in Table 1. Of note is that all three cohorts had a mean PaO2/
FiO2 <100. The majority of the patients had at least one comorbidity 
(Table 1). The hydrocortisone cohort had a higher SOFA score and 
mean C-reactive protein compared with the other cohorts.
The majority of the patients in all three groups received enoxaparin 
1 mg/kg bd (81 of 88 patients in the hydrocortisone group, 46 
of 46 in the methylprednisolone group, and 106 of 108 in the 
dexamethasone group). We could not demonstrate any statistically or 
clinically significant difference in the outcome of patients with critical 
COVID-19 treated with high-dose intravenous hydrocortisone 
or methylprednisolone compared with a relatively lower dose of 
dexamethasone (survival rates 38.6%, 39.1% and 33.3%, respectively; 
p=0.68). Patients treated with methylprednisolone tended to have a 
shorter length of ICU stay (median (IQR) 6 (4 - 10), 4 (2 - 8) and 
5 (2 - 8) days; p=0.015) and fewer episodes of nosocomial sepsis 
(47.7%, 32.6% and 48.1%; p=0.01).
Discussion
In this single-centre observational study of 242 patients managed 
in a COVID-19-dedicated ICU we could not demonstrate any 
statistically or clinically significant difference in the outcome of 
patients with critical COVID-19 treated with high-dose intravenous 
hydrocortisone or methylprednisolone compared with a relatively low 
dose of dexamethasone. Patients treated with methylprednisolone 
tended to have a shorter length of ICU stay and fewer cases of 
nosocomial sepsis.
Prior to the landmark RECOVERY trial,[11] no pharmacological 
intervention had shown a clear mortality benefit in severe and critical 
COVID-19 disease. The investigators reported that dexamethasone 
reduced death by one-third in patients receiving invasive ventilation 
and by one-fifth in patients receiving oxygen without invasive 
ventilation. There was no evidence of benefit in steroid use for those 
not receiving respiratory support.[11] At our institution, these findings 
led to an immediate change in the standard of care with regard to 
corticosteroids.
Pre-RECOVERY, the expert opinion regarding steroid use 
was variable, with poor-quality data from mostly observational 
studies pertaining to SARS, MERS and influenza guiding current 
management and opinion, stating the need for more robust 
randomised control trials (RCTs). As per WHO recommendation, 
steroid use was discouraged, but studies assisting in the evaluation 
of its efficacy and safety were prioritised. Subsequently, the WHO 
Rapid Evidence Appraisal for COVID-19 Therapies (REACT) 
Working Group evaluated corticosteroid therapy and 28-day 
mortality in severe and critical COVID-19 disease in a meta-analysis 
of seven RCTs involving institutions in 12 countries with different 
corticosteroids at differing doses.[13-16] Their findings echoed those 
of RECOVERY, with the main mortality benefit shown in those 
who are critically ill, and showed similar mortality benefit for 
dexamethasone and hydrocortisone.[13-16]
In the WHO review of two meta-analyses of eight RCTs, it was 
estimated that the use of corticosteroids resulted in 87 fewer deaths 
per 1 000 critically ill patients and 67 fewer deaths per 1 000 patients 
in the severely ill cohort.[15] They defined critical COVID-19 by the 
criteria for acute respiratory distress syndrome, sepsis, septic shock 
or other conditions that would normally require the provision of 
life-sustaining therapies such as invasive or non-invasive mechanical 
ventilation.[15] Their findings aligned with those of the REACT group 
regarding adverse events, except noting a possible increase in episodes 
of hyperglycaemia and hypernatraemia.[15] Current WHO guidelines 
include corticosteroid therapy as part of the standard of care in 
the management of the severe and critically ill COVID-19 patient, 
advocating 6 mg of dexamethasone orally or intravenously daily or 50 
mg of hydrocortisone intravenously 8-hourly for 7 - 10 days.[15]
The initial arbitrary daily dose of 6 mg dexamethasone in the 
RECOVERY trial was given on the premise that higher doses were 
likely to be associated with harm and delayed viral clearance.[11] 
The REACT meta-analysis noted that while a formal comparison 
552       June 2021, Vol. 111, No. 6
IN PRACTICE
between a higher- and lower-dose corticosteroid and its association 
with mortality was not possible, a higher dose of corticosteroids 
was unlikely to have additional benefit.[16] In our cohorts using a 
higher dose hydrocortisone and methylprednisolone, there was 
no statistically significant mortality benefit. However, a recent 
review of the pharmacological principles guiding prolonged 
glucocorticoid treatment in ARDS suggested a potential superior 
response to a higher dose of corticosteroid administration by 
maximising glucocorticoid receptor saturation.[17] The review also 
favours an individualised course of corticosteroids, uniquely tailored 
to individual inflammatory response, as well as a gradual tapering to 
prevent a rebound inflammatory response. Meduri and colleagues[17,18] 
further stated that prolonged, higher-dose corticosteroid therapy was 
associated with a decrease in complications probably related to a 
shorter time of mechanical ventilation. Our data suggest that patients 
treated with a higher dose of methylprednisolone compared with 
the standard-dose dexamethasone had a shorter length of ICU stay 
and fewer episodes of nosocomial sepsis, consistent with the authors’ 
findings.
In the SA NDoH review of potential therapies,[8] the routine 
use of agents such as lopinavir-ritonavir, ivermectin, remdesivir 
and tocilizumab has been discouraged based on present available 
evidence showing no mortality benefit. A review of the available 
evidence, as well as a review of the WHO meta-analysis pertaining 
to corticosteroid therapy in the management of severe and critical 
COVID-19, concluded that corticosteroid therapy is indicated in the 
treatment of hospitalised patients needing respiratory support (either 
invasive or non-invasive oxygen therapy).[8] COVID-19 has affected 
both high- and low-income countries, and it is of importance that 
there should be equitable access to and distribution of therapeutic 
agents that have proven mortality benefit. Corticosteroids are 
inexpensive and widely available, and therefore a feasible option for 
a developing region such as southern Africa to use in a widespread 
manner.
Table 1. Baseline characteristics and main outcomes of the three cohorts
Hydrocortisone (N=88) Methylprednisolone (N=46) Dexamethasone (N=108) p-value
Demographics 
Age (years), median (IQR) 54.0 (44 - 60) 52.0 (47.5 - 59.0) 54.5 (46 - 62) 0.58
Sex (male), n (%) 53 (60.2) 32 (69.6) 56 (51.9) 0.11
Comorbidities, n (%) 
Type 2 DM 52 (59.1) 24 (52.2) 47 (43.5) 0.09
Hypertension 42 (47.7) 25 (54.3) 63 (58.3) 0.33
HIV 17 (19.3) 4 (8.7) 16 (14.8) 0.02
Indices of severity, median (IQR) 
PaO2/FiO2 ratio 60 (51 - 87) 61.5 (49.8 - 85.3) 59.5 (44.8 - 82) 0.87
SOFA 4 (3 - 5) 4 (3 - 4) 3 (2 - 4) <0.01
Special investigations, median (IQR)
WCC (× 109/L) 11.7 (9.1 - 15.7) 11.2 (9.0 - 14.8) 11.8 (8.9 - 15.5) 0.95
Neutrophil count (× 109/L) 8.6 (6.3 - 11.5) 9.7 (7.3 - 12.0) 10.5 (7.7 - 13.0) 0.12
Lymphocyte count (× 109/L) 1. (0.7 - 1.4) 1.0 (0.8 - 1.3) 0.8 (0.6 - 1.1) 0.01
N/L ratio 8.58 (5.50 - 13.18) 9.2 (6.4 - 14) 12.8 (8.1 - 17.8) 0.001
CRP (mg/L) 245 (142.0 - 331) 188 (121.8 - 316.8) 177 (119.3 - 279.3) 0.014
PCT (µg/L) 0.56 (0.25 - 1.65) 0.55 (0.2 - 2.4) 0.5 (0.23 - 1.0) 0.13
Ferritin (µg/L) 1 370 (799 - 2 305) 1 412 (898 - 2 890.8) 843 (458.5 - 1 284.8) 0.001
D-dimer (mg/L) 1.2 (0.4 - 9.15) 1.43 (0.4 - 13.1) 1.01 (0.63 - 3.76) 0.76
Trop T (ng/L) 11 (6 - 21) 16 (8 - 34) 15 (8.25 - 39.8) 0.26
HbA1c (%) 7.4 (6.5 - 101) 6.8 (6.1 - 8.7) 6.6 (6.1 - 10.0) 0.38
Creatinine (µmol/L) 70 (60 - 87) 73.5 (63.8 - 100.3) 65.5 (57 - 83) 0.94
eGFR (mL/min/1.73 m2) 98 (82 - 110) 96 (76.3 - 107.3) 98.5 (82 - 107.8) 0.38
Survival, n (%) 
ICU 34 (38.6) 18 (39.1) 36 (33.3) 0.68
Hospital 34 (38.6) 18 (39.1) 33 (30.6) 0.23
Failed HFNO, n (%) 
Intubated 47 (53.4) 23 (50.0) 69 (63.9) 0.18
Sudden death 6/52 (11.5) 6/27 (22.2) 13/71 (18.3) 0.42
Overall 48/80 (60.0) 26/43 (65.1) 69/97 (71.1) 0.12
Length of stay (days), median (IQR) 
Overall 7 (4 - 10) 5 (3 - 9) 6 (3.9 - 10) 0.08
ICU 6 (4 - 10) 4 (2 - 8) 5 (2 - 8) 0.015
Complications, n (%)
Nosocomial sepsis 42 (47.7) 15 (32.6) 52 (48.1) 0.01
AKI 34 (38.6) 13 (28.3) 44 (40.7) 0.76
IQR = interquartile range; DM = diabetes mellitus; PaO2/FiO2 = arterial oxygen partial pressure to fraction of inspired oxygen ratio; SOFA = sequential organ failure assessment;  
WCC = white cell count; N/L ratio = neutrophil to lymphocyte ratio; CRP = C-reactive protein; PCT = procalcitonin; HbA1c = glycated haemoglobin;  
eGFR = estimated glomerular filtration rate; ICU = intensive care unit; HFNO = high-flow nasal oxygen; AKI = acute kidney injury.
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Study strengths and limitations
The main strength of our study is that standard therapy and 
disease severity of patients admitted to the ICU remained largely 
unchanged apart from the choice of steroid therapy. The main 
limitations of our study are the lack of randomisation to the type 
of corticosteroid used and the lack of a control group (who did not 
receive any corticosteroids). Furthermore, relatively few patients 
received methylprednisolone, which may limit the generalisability of 
our finding with regard to a shortened length of ICU stay and fewer 
episodes of nosocomial sepsis. Other limitations include the lack of 
Kidney Disease Improving Global Outcomes (KDIGO) acute kidney 
injury (AKI) staging data and subsequent need for dialysis and the 
use of other COVID-related illness severity scores to further assess 
AKI and disease severity in our cohorts.
Conclusions
Our data further support evidence that hydrocortisone or 
methylprednisolone can be given as an alternative to dexamethasone 
in the management of patients with critical COVID-19, and that this 
is a feasible alternative, especially in resource-constrained settings.
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